EPHB4 and soft tissue sarcoma: We have noticed that anti-EPHA2 and anti-EPHB4 as well as anti-ephrin-B1 therapeutic agents (Table 3) have been explored in bone and soft tissue sarcomas, albeit they could have also been tried in the clinical setting.